Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MC5R | P33032 | 2/20 | 0.63 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.63 |
| ▸ | SOX18 | P35713 | 1/20 | 0.55 |
| ▸ | AKR1B1 | P15121 | 1/20 | 0.54 |
| ▸ | F10 | P00742 | 1/20 | 0.47 |
| ▸ | CYP1A2 | P05177 | 3/20 | 0.47 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.47 |
| ▸ | DAO | P14920 | 1/20 | 0.46 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.46 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.46 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.46 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.45 |
| ▸ | HTR2A | P28223 | 1/20 | 0.44 |
| ▸ | HTR2C | P28335 | 1/20 | 0.44 |
| ▸ | HTR2B | P41595 | 1/20 | 0.44 |
| ▸ | MC4R | P32245 | 1/20 | 0.44 |
| ▸ | MC3R | P41968 | 1/20 | 0.44 |
| ▸ | MC1R | Q01726 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31509450 | 0.83 | MAPK1 (0.65) | MC5RMAPK1CYP1A2CYP2A6CYP2C9 | |
| SCHEMBL7915037 | 0.83 | MAPK1 (0.65) | MC5RMAPK1CYP1A2CYP2A6CYP2C9 | |
| SCHEMBL3047898 | 0.82 | CYP1A2 (0.62) | AKR1B1CYP1A2CYP2A6DAOCYP2C9 | |
| SCHEMBL29560700 | 0.82 | CYP1A2 (0.65) | MC5RSOX18CYP1A2CYP2A6SIGMAR1 | |
| SCHEMBL6240981 | 0.82 | CYP1A2 (0.65) | MC5RSOX18CYP1A2CYP2A6SIGMAR1 | |
| SCHEMBL1826164 | 0.80 | CYP1A2 (0.52) | AKR1B1CYP1A2DAOSIGMAR1CYP2C9 | |
| SCHEMBL49863 | 0.79 | CYP1A2 (0.69) | MC5RMAPK1CYP1A2CYP2A6SIGMAR1 | |
| SCHEMBL5778428 | 0.79 | MC5R (0.59) | MC5RMAPK1CYP1A2CYP2A6CYP2C9 | |
| SCHEMBL6192739 | 0.79 | BACE1 (0.53) | AKR1B1DAO | |
| SCHEMBL7069796 | 0.78 | AKR1B1 (0.47) | MC5RMAPK1AKR1B1CYP1A2DAO |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 27 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2448956-B1 | SOLID PHASE PEPTIDE SYNTHESIS OF PEPTIDE ALCOHOLS | CENTRE NAT RECH SCIENT (FR) | 2018-05-16 | — | — | EP | disclosed |
| US-9206222-B2 | Solid phase peptide synthesis of peptide alcohols | CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (FR) | 2015-12-08 | — | — | US | disclosed |
| EP-2448956-A1 | SOLID PHASE PEPTIDE SYNTHESIS OF PEPTIDE ALCOHOLS | Centre National De La Recherche Scientifique CNRS (FR) | 2012-05-09 | — | — | EP | disclosed |
| US-20120108748-A1 | SOLID PHASE PEPTIDE SYNTHESIS OF PEPTIDE ALCOHOLS | CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (FR) | 2012-05-03 | — | — | US | disclosed |
| WO-2011000848-A1 | SOLID PHASE PEPTIDE SYNTHESIS OF PEPTIDE ALCOHOLS | CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (CNRS) (FR) | 2011-01-06 | — | — | WO | disclosed |
| EP-2270025-A1 | Solid phase peptide synthesis of peptide alcohols | Centre National pour la Recherche Scientifique (CNRS) (FR) | 2011-01-05 | — | — | EP | disclosed |
| US-20060128756-A1 | Heteroaryl-substituted pyrrole derivatives, their preparation and their therapeutic uses | SANKYO COMPANY, LIMITED (JP) | 2006-06-15 | — | — | US | disclosed |
| US-6753409-B1 | FOR TREATMENT OF MYOCARDIAL INFARCTION, STROKE, PERIPHERAL ARTERIAL DISEASE AND DISSEMINATED INTRAVASCULAR COAGULATION | AVENTIS PHARMACEUTICALS INC. | 2004-06-22 | — | — | US | disclosed |
| EP-1030831-A4 | PROCESS FOR THE PREPARATION OF AZACYCLOALKYLALKANOYL PSEUDOTETRAPEPTIDES | AVENTIS PHARM PROD INC (US) | 2003-01-02 | — | — | EP | disclosed |
| US-20020002268-A1 | Antithrombotic azacycloalkylalkanoyl peptides and pseudopeptides | AVENTIS PHARMACEUTICALS INC. | 2002-01-03 | — | — | US | disclosed |
| EP-0929572-A1 | ANTITHROMBOTIC AZACYCLOALKYLALKANOYL PEPTIDES AND PSEUDOPEPTIDES | RHONE-POULENC RORER PHARMACEUTICALS, INC. (US) | 1999-07-21 | — | — | EP | disclosed |
| EP-0923553-A1 | STABLE NON-HYGROSCOPIC CRYSTALLINE FORM OF N- N-N-(4-(PIPERIDIN-4-YL)BUTANOYL)-N-ETHYLGLYCYL] COMPOUNDS | RHONE-POULENC RORER PHARMACEUTICALS, INC. (US) | 1999-06-23 | — | — | EP | disclosed |
| WO-1999019294-A1 | PROCESS FOR THE PREPARATION OF AZACYCLOALKYLALKANOYL PSEUDOTETRAPEPTIDES | AVENTIS PHARMACEUTICALS PRODUCTS INC. LEGAL/PATENTS (US) | 1999-04-22 | — | — | WO | disclosed |
| EP-0812205-A4 | ANTITHROMBOTIC AZACYCLOALKYLALKANOYL PEPTIDES AND PSEUDOPEPTIDES | RHONE POULENC RORER PHARMA (US) | 1999-03-31 | — | — | EP | disclosed |
| US-5866685-A | Antithrombotic azacycloalkylalkanoyl peptides and pseudopeptides | RHONE-POULENC RORER PHARMACEUTICALS INC. (US) | 1999-02-02 | — | — | US | disclosed |
| US-5780590-A | Antithrombotic azacycloalkylalkanoyl peptides and pseudopeptides | RHONE-POULENC RORER PHARMACEUTICALS INC. (US) | 1998-07-14 | — | — | US | disclosed |
| WO-1998017678-A1 | ANTITHROMBOTIC AZACYCLOALKYLALKANOYL PEPTIDES AND PSEUDOPEPTIDES | RHONE-POULENC RORER PHARMACEUTICALS INC. (US) | 1998-04-30 | — | — | WO | disclosed |
| WO-1998007696-A1 | STABLE NON-HYGROSCOPIC CRYSTALLINE FORM OF N-[N-N-(4-(PIPERIDIN-4-YL)BUTANOYL)-N-ETHYLGLYCYL] COMPOUNDS | RHONE-POULENC RORER PHARMACEUTICALS INC. (US) | 1998-02-26 | — | — | WO | disclosed |
| EP-0812205-A1 | ANTITHROMBOTIC AZACYCLOALKYLALKANOYL PEPTIDES AND PSEUDOPEPTIDES | RHONE-POULENC RORER PHARMACEUTICALS INC. (US) | 1997-12-17 | — | — | EP | disclosed |
| WO-1995010295-A1 | ANTITHROMBOTIC AZACYCLOALKYLALKANOYL PEPTIDES AND PSEUDOPEPTIDES | RHONE-POULENC RORER PHARMACEUTICALS INC. (US) | 1995-04-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020002268-A1 | Antithrombotic azacycloalkylalkanoyl peptides and pseudopeptides | PLAT, SELP, PIGS | MC5R 2369/4885MAPK1 3313/4885SOX18 4065/4885 |
| US-20120108748-A1 | SOLID PHASE PEPTIDE SYNTHESIS OF PEPTIDE ALCOHOLS | VIP, ERG28, PSAP | MC5R 4023/4885MAPK1 2201/4885SOX18 3458/4885 |
| US-20060128756-A1 | Heteroaryl-substituted pyrrole derivatives, their preparation and their therapeutic uses | IL2, IL1A, IL1B | MC5R 1933/4885MAPK1 2616/4885SOX18 4481/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.